What changed for Migraine
A plain English summary of what recently moved in the public data Voxsanity tracks for Migraine. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting worldwide 169 to 173 (+4)
- Trials on record 1,576 to 1,586 (+10)
Newly subsidised on the PBS
No medicines were newly subsidised on the PBS for Migraine in July 2026. Voxsanity tracks 10 PBS-subsidised medicines for this condition; none of them was listed for the first time this month.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 119 trials tracked for Migraine that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT05989048 · results posted 22 May 2026
According to the results reported on ClinicalTrials.gov, this trial looked at a nasal spray medicine called zavegepant compared to a dummy spray (placebo) for the treatment of migraine. A total of 708 people were assigned to the zavegepant group and 706 to the placebo group, with the vast majority completing the trial. The trial was measuring two main things at two hours after taking the spray: whether participants reported being completely free of head pain, and whether they were free from their most bothersome migraine symptom — which each participant had nominated beforehand from nausea, se...
-
NCT05518123 · results posted 22 May 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 658 people in total — 330 in one group and 328 in another. The trial was set up in two stages: a 12-week "double-blind" phase (where neither participants nor researchers knew who was receiving the active medicine, rimegepant, or a dummy pill called a placebo), followed by an open-label phase where everyone received rimegepant. The main thing the trial was measuring was how much the number of migraine days per month changed compared to a baseline observation period recorded before treatment began. The reported data sh...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05509400 · results posted 21 April 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT05509400) enrolled 633 people in total — 317 in one group and 316 in another. In the first part of the trial (the "double-blind" phase), participants were randomly assigned to take either rimegepant or a placebo (a dummy pill with no active ingredient) when they had a migraine attack, without knowing which one they received. The trial was primarily measuring how many people experienced pain relief two hours after taking their assigned treatment. Most participants then moved into a second open-label phase, where everyone re...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04404439 · results posted 16 April 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 78 people who experienced tinnitus (ringing or noise in the ears). Participants were randomly assigned to one of three groups: 23 people received a combination of nortriptyline and topiramate, 28 received a combination of verapamil and paroxetine, and 27 received a placebo (a dummy treatment with no active ingredients). The trial's main goal was to measure changes in how much tinnitus affected participants' daily lives, using a questionnaire called the Tinnitus Functional Index (TFI), which is scored from 0 to 100 — w...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03844412 · results posted 19 March 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT03844412) enrolled 209 participants across four groups: a combined treatment group (52 people), a peripheral treatment-only group (52 people), a central treatment-only group (52 people), and a placebo group (53 people). The trial was measuring pain and wellbeing in people with a condition called vestibulodynia — a type of vulvar pain — using several questionnaires and a tampon insertion test. Not everyone who started finished the trial: completion numbers ranged from 34 people in the peripheral treatment group to 47 in the...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03982316 · results posted 11 March 2026
According to the results reported on ClinicalTrials.gov, this trial looked at a telehealth-based programme called Telehealth Behavioral Migraine Management (TeleBMM) for people with migraines. The trial had three groups: TeleBMM, an Education Modules group, and a Cognitive Behavioural Therapy group. In total, 20 people started the study (14 in TeleBMM, 6 in Education Modules, and nobody was enrolled in the third group). Of those, 9 people completed the study (7 from TeleBMM and 2 from Education Modules), while 11 did not finish. The reported data shows that the main thing the study was measur...
-
NCT03592329 · results posted 25 February 2026
According to the results reported on ClinicalTrials.gov, this trial looked at people with migraines and a group of healthy volunteers. A total of 136 people started the study across five groups: two groups received active transcutaneous vagus nerve stimulation (tVNS — a mild electrical stimulation applied to the ear) combined with either mindfulness-based stress reduction (MBSR) or a non-emotional control programme (NEC); two groups received a sham (inactive) version of the same stimulation paired with the same programmes; and one group of healthy volunteers was included for comparison. Of tho...
-
NCT06874361 · results posted 10 February 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 156 people in total — 77 in the active treatment group and 79 in the sham (inactive/placebo-style) group. Of those, 61 and 64 respectively completed the study. The trial was measuring whether the active treatment could reduce migraine headache pain and related symptoms compared to a sham version of the same treatment, looking at outcomes at 2 hours and 24 hours after treatment. The reported data shows that for the main outcome — being completely free of pain at 2 hours — 15 participants in the active treatment group...
-
NCT05028569 · results posted 9 December 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05028569) looked at two different doses of BOTOX (155 units and 195 units) compared to a dummy injection (placebo) in people with migraine. A total of 775 people entered the initial screening phase, and 775 were then split into three groups for the main double-blind phase — meaning neither the participants nor the researchers knew who was receiving which treatment. The trial was primarily measuring how the number of migraine days per month changed over months 5 and 6 of the study, and also tracked adverse events (unwanted...
-
NCT05452239 · results posted 4 December 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled around 608 participants (approximately 305 in the eptinezumab group and 303 in the placebo group). The trial was looking at people with chronic migraine and was measuring changes in the number of migraine days per month over a placebo-controlled period, followed by an open-label period where everyone received the active treatment. The main thing being tracked was how many migraine days per month participants experienced compared to where they started. The reported data shows that, for the primary outcome — change in...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01899040 · results posted 31 May 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT01899040) enrolled 100 people in total across three groups: 50 used an active device, 30 used a fully inactive placebo device, and 20 used a partially active placebo device. The trial was measuring whether using the device affected the number of days per month that participants experienced migraines, as well as a range of other measures including headache pain scores, mood, balance, and mental processing speed. By the end of the study, 42, 22, and 17 participants completed the trial in each of the three groups respectively...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03706794 · results posted 6 April 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03706794) involved 18 people in total — 8 in a group that used a Clinical Decision Support Tool and 10 in a group that received Headache Education. All 18 participants completed the study. The trial was measuring how well people with migraines stuck to recommended management strategies, such as taking migraine medication early (while pain was still mild), avoiding overuse of medication, following behavioural strategies like managing stress, sleep, and eating habits, and taking any prescribed preventive medication consisten...
-
NCT03381261 · results posted 24 March 2025
According to the results reported on ClinicalTrials.gov, this trial involved 37 people who experience chronic migraines on both sides of their head. The trial used a "split-person" design, meaning each participant served as their own comparison — one side of their head received an injection of onabotulinumtoxin A (a medication sometimes used for migraines), while the other side received no injection. Tissue samples were then collected from both sides during a separate migraine-related surgery the participants were already scheduled to have. The samples were analysed to look at the activity of...
-
NCT05264129 · results posted 8 October 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT05264129) involved 262 participants and was set up in two back-to-back phases. In the first phase (weeks 1–12), all 262 participants took a daily preventive migraine tablet called atogepant (60 mg); 221 of them completed this phase. In the second phase (weeks 12–24), 218 of those participants moved on to take atogepant together with a separate migraine tablet called ubrogepant (100 mg), and 203 of them completed that phase. The trial's primary focus was on monitoring and recording safety-related information — specifically...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04613362 · results posted 19 September 2024
According to the results reported on ClinicalTrials.gov, this trial (known as TENACITY) involved 57 people in total — 30 in a group that received a telehealth version of Cognitive Behavioural Therapy (a talking-based approach to managing thoughts and behaviours) specifically designed for migraine, and 27 in a comparison group who received what the trial called "behavioural usual care." The trial was measuring two main things: the number of headache days participants experienced at three months, and the costs involved in setting up and running each program. It also tracked several other measure...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05127486 · results posted 18 June 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT05127486) enrolled 580 adults in total — 287 in the galcanezumab group and 293 in the rimegepant group — all of whom received at least one dose of their assigned study drug. The trial ran for three months and was primarily measuring the proportion of participants whose monthly migraine headache days fell by at least half compared to where they started (called a "50% response rate"). A number of secondary measures were also tracked, including larger reductions in migraine days and month-by-month changes. The reported data...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04498910 · results posted 28 November 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT04498910) enrolled 38 people in total — 19 received a drug called LY3451838 (at a dose of 1,500 mg) and 19 received a placebo (a dummy treatment with no active ingredient). The trial was measuring changes in the number of days per month that participants experienced migraine headaches, comparing those who received the study drug against those who received the placebo. The reported data shows that, over a one-month period (the main thing the trial was set up to measure), people in the LY3451838 group reported an average re...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03150797 · results posted 13 October 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT03150797) looked at whether melatonin could reduce the number of migraine or migraine-like headache days in children and adolescents. The trial had two phases. First, 72 participants went through a single-blind run-in phase (where everyone received a placebo, meaning a dummy pill), and 59 of them completed it. Then 42 participants moved into the main double-blind phase — 14 in each group: melatonin 3mg, melatonin 6mg, and placebo. In the double-blind phase (where neither participants nor researchers knew who was getting wh...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03971071 · results posted 13 October 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT03971071) looked at erenumab — a preventive migraine injection — in people who were overusing acute headache medications (a condition sometimes called "medication overuse headache," or MOH). A total of 620 adults took part in the main double-blind phase, split roughly equally into three groups: one receiving a placebo (dummy injection), one receiving a 70 mg dose of erenumab, and one receiving a 140 mg dose. Participants were tracked over six months to see whether their pattern of medication use changed. After the double-b...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04936061 · results posted 29 September 2023
According to the results reported on ClinicalTrials.gov, this trial tested a device called CoolStat on 24 people with migraine headaches. Participants were split into three groups: 6 people received a high-flow treatment, 9 received a low-flow treatment, and 9 received a sham (dummy) treatment using ordinary ambient air. All 24 participants completed the study. The trial was measuring how many people experienced pain relief two hours after using the device, as well as how well participants tolerated the device and how many experienced device-related unwanted events. The reported data shows th...
-
NCT04740827 · results posted 21 September 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT04740827) enrolled 158 people in the placebo group and 157 people in the atogepant 60 mg group, for a total of 315 participants. The trial ran for 12 weeks and was measuring whether a daily tablet called atogepant (60 mg) reduced the number of days per month that people experienced migraines and headaches, compared with a placebo (a dummy tablet with no active ingredient). Participants kept a daily diary to record their migraine and headache days throughout the study. The reported data shows that, at the start of the tria...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03338920 · results posted 24 July 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT03338920) enrolled 159 people who experienced migraines — 79 were given a sumatriptan nasal powder and 80 received a placebo (a dummy treatment with no active ingredient). The trial was measuring how many participants reported being completely free of headache pain two hours after taking their assigned treatment. Most participants completed the study — 75 in the sumatriptan group and 74 in the placebo group. The reported data shows that at the two-hour mark, 8 out of 79 participants in the sumatriptan nasal powder group r...
-
NCT04940390 · results posted 24 July 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT04940390) enrolled a total of 1,591 participants — 796 in the STS101 5.2 mg group and 795 in the placebo group (a placebo is a dummy treatment with no active ingredient, used for comparison). The trial was measuring how people with migraine responded two hours after taking either STS101 or the placebo, looking specifically at pain levels and troublesome symptoms like sensitivity to light, sensitivity to sound, and nausea. The reported data shows that for the first main outcome — complete freedom from migraine headache pai...
-
NCT04406649 · results posted 3 July 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT04406649) enrolled 482 people, all of whom received a treatment called STS101 at a dose of 5.2 mg. Of those who started, 205 completed the study and 277 did not complete it. The trial was measuring two main things during migraine attacks: first, whether participants became completely free of head pain and stayed that way from 2 hours up to 48 hours after taking the treatment; and second, whether their single most bothersome migraine symptom — chosen from nausea, sensitivity to light, or sensitivity to sound — also went awa...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03901482 · results posted 29 June 2023
According to the results reported on ClinicalTrials.gov, this trial enrolled 1,201 people across three groups: those who received a low dose of STS101 (399 people), a high dose of STS101 (400 people), or a placebo — a dummy treatment with no active ingredient (402 people). The trial was measuring how STS101, a treatment for migraine, performed against placebo two hours after a single dose was taken during a migraine attack. Around 363–368 people in each group completed the study. The reported data shows two main things were measured at two hours after taking the dose. The first was "pain free...
-
NCT00812214 · results posted 15 June 2023
According to the results reported on ClinicalTrials.gov, this trial enrolled 79 people in total — 38 received a 3 mg dose of eszopiclone (a sleep medication) and 41 received a placebo (a dummy pill with no active ingredient). The trial was looking at how the two groups compared on sleep-related measures, including how long people slept each night, how often they woke up, their self-rated sleep quality, daytime alertness and fatigue, and how frequently they had headaches. Participants kept a daily diary throughout the study, and their responses were averaged over the six-week treatment period....
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04492020 · results posted 31 May 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT04492020) enrolled 518 adults across two treatment sequences (264 in Sequence A and 254 in Sequence B). The trial was a crossover study, meaning participants took both a placebo and ubrogepant 100 mg (a migraine medicine) at different points, during the early warning phase of a migraine — before a headache fully develops. The main thing the trial was measuring was whether participants avoided a moderate or severe headache in the 24 hours after taking the study treatment during that early warning phase. The reported data s...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04829747 · results posted 24 May 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT04829747) enrolled 3 participants, all of whom received the study drug, atogepant. Two participants completed the trial and one did not. The trial was primarily focused on monitoring participants for any medical events or changes in their health measurements — specifically looking at adverse events (unexpected medical occurrences), blood and laboratory test results, vital signs such as blood pressure and pulse, heart tracings (ECGs), and any changes in thoughts of self-harm assessed using a standard rating scale. The repo...
-
NCT04698525 · results posted 17 May 2023
According to the results reported on ClinicalTrials.gov, this trial enrolled 33 people in total — 17 in the valproate group and 16 in the memantine group — to compare two medications used to try to prevent episodic migraine (migraines that occur on a limited number of days per month). The trial ran for three months and measured three main things before and after treatment: how many days per month participants experienced migraine, how painful those migraines were (rated on a 0–10 scale where 0 means no pain and 10 means the worst imaginable pain), and how much migraines were affecting daily li...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03855137 · results posted 14 February 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT03855137) enrolled 778 people across three groups: 259 received a placebo (a dummy pill with no active ingredient), 257 received atogepant 30 mg twice daily, and 262 received atogepant 60 mg once daily. The trial ran for 12 weeks and was measuring changes in the number of migraine days per month, headache days per month, and the number of days per month that participants took acute (rescue) medication for their migraines. Participants kept a daily diary to record this information. The reported data shows that, on average,...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
See all 119 reported results for Migraine
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, a substantial amount of public research funding is currently being directed toward migraine research. The year on year direction of this funding has remained broadly steady, suggesting that migraine continues to be treated as a meaningful research priority rather than an emerging or fading area of interest. For patients, this kind of sustained investment generally me...
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.